Galapagos and Genentech extend drug discovery deal
Agreement has now been extended three times since 2005
Galapagos’ service division Argenta has signed a £21.5m (US$35.5m; €23.4m) extension to its contract drug discovery agreement with Genentech.
Medicinal chemistry, in vitro biology and screening will be performed to discover new chemical entities against undisclosed drug targets chosen by Genentech.
This is the third extension since the firms started working together in December 2005.
The extended agreement also allows Genentech to continue placing projects directly with Galapagos' other service division, BioFocus, which will provide Genentech with integrated medicinal chemistry, in vitro biology and ADME services.
BioFocus has been working with Genentech since an amendment to the Argenta agreement was signed in September 2010.